[go: up one dir, main page]

MX9704727A - Composicion para el tratamiento de tumores malignos y sus metastasis. - Google Patents

Composicion para el tratamiento de tumores malignos y sus metastasis.

Info

Publication number
MX9704727A
MX9704727A MX9704727A MX9704727A MX9704727A MX 9704727 A MX9704727 A MX 9704727A MX 9704727 A MX9704727 A MX 9704727A MX 9704727 A MX9704727 A MX 9704727A MX 9704727 A MX9704727 A MX 9704727A
Authority
MX
Mexico
Prior art keywords
tumor
lactose
metastasis
cytotoxic
malignant tumors
Prior art date
Application number
MX9704727A
Other languages
English (en)
Other versions
MXPA97004727A (es
Inventor
David Rubin
Original Assignee
Co Enzyme Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Co Enzyme Technology Ltd filed Critical Co Enzyme Technology Ltd
Publication of MX9704727A publication Critical patent/MX9704727A/es
Publication of MXPA97004727A publication Critical patent/MXPA97004727A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se puede inhibir la formacion de metastasis de tumores malignos administrando a un paciente que tenga necesidad de ello, suficiente lactosa para bloquear las lectinas cruciales en el organo afectado, de manera que las células tumorales no pueden anclarse a otros lugares del cuerpo. Se puede administrar la lactosa sola o en combinacion con conjugados o fármacos citotoxicos. De preferencia se conjuga la lactosa con un sustancia citotoxica, de manera que se trate el tumor primario circurrentemente con la prevencion de la metastasis. Adicionalmente, al conjugar un fármaco citotoxico con la lactosa, se mantiene el fármaco citotoxico en proximidad íntima con el tumor, debido a los receptores en el tumor, que unen la lactosa (y, por consiguiente, el agente citotoxico unido a ella) a las células tumorales. Al utilizar un conjugado de lactosa con un agente citotoxico, generalmente es suficiente una dosis para destruir los sitios receptores en el tumor y prevenir la metastasis del tumor, al mismo tiempo que se trata el tumor.
MXPA/A/1997/004727A 1994-12-21 1995-11-27 Composicion para el tratamiento de tumoresmalignos y sus metastasis MXPA97004727A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08360352 1994-12-21
US08/360,352 US5639737A (en) 1991-11-04 1994-12-21 Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors

Publications (2)

Publication Number Publication Date
MX9704727A true MX9704727A (es) 1998-06-30
MXPA97004727A MXPA97004727A (es) 1998-10-30

Family

ID=

Also Published As

Publication number Publication date
ATE235257T1 (de) 2003-04-15
AU692021B2 (en) 1998-05-28
DE69530109D1 (de) 2003-04-30
EP0797453B1 (en) 2003-03-26
EP0797453A1 (en) 1997-10-01
IL116465A (en) 2010-04-29
DE69530109T2 (de) 2004-02-05
US5639737A (en) 1997-06-17
CA2208206A1 (en) 1996-06-27
WO1996019243A1 (en) 1996-06-27
CA2208206C (en) 2008-02-12
IL116465A0 (en) 1996-03-31
AU4240796A (en) 1996-07-10

Similar Documents

Publication Publication Date Title
IL116465A0 (en) Pharmaceutical antitumor composition
Lissoni Is there a role for melatonin in supportive care?
Laske et al. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice
Goff et al. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model
Navari et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
Folkman Role of angiogenesis in tumor growth and metastasis
TR200202231T2 (tr) Amiloidojenik hastalığın önlenmesi ve tedavisi
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
FI974268A0 (fi) Flavanolignaanien käyttö lääkkeiden, joilla on lisääntymistä torjuvaa vaikutusta kohdussa, munasarjoissa ja rintarauhasessa, valmistamiseksi
MX9302038A (es) Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
AR020051A1 (es) Procedimiento de uso y uso de una combinacion de un anticuerpo anti-erbb2 y un agente quimicoterapeutico distinto de un derivado de antraciclina para la manufactura de un medicamento util para el tratamiento de cancer
CY1112361T1 (el) Σκευασματα για αντικαρκινικη θεραπεια που περιεχουν εκτεϊνασκιδινη 743
AR009757A1 (es) USO DEL COMPUESTO CETRORELIX PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE BPH O CÁNCER DE PRoSTATA EN UN MAMíFERO(
ES2082959T3 (es) Procedimiento para desarrollar la sintesis de una droga contraceptiva y de control del ciclo menstrual que tiene propiedades anticinetosicas, oncostaticas y terapeuticas para el tratamiento de los tumores de mama y melanomas.
KR950031106A (ko) 종양 및 염증성 질환의 선택적 치료를 위한 괴사-유발물질과 괴사에 의해 활성화되는 물질과의 배합물
Kranjc et al. Radiosensitising effect of electrochemotherapy with bleomycin in LPB sarcoma cells and tumors in mice
KR960700063A (ko) 사람 종양 세포내에서의 테모졸로마이드의 강화방법(Potentiation of temozolomide in human tumour cells)
Kaminski et al. Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
Ariel Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
ES2205215T3 (es) Inhibicion del crecimiento y erradicacion de tumores solidos usando un modulador de prolactina y un fotosensibilizador.
CR20240385A (es) Terapias combinadas para el tratamiento del cáncer que comprenden un conjugado de farmaco anticuerpo b7-h4